SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    von der Maase H,Hansen S,Roberts J, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 30683077.
  • 2
    Roth BJ,Dreicer R,Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994; 12: 22642270.
  • 3
    Sweeney C,Roth B,Kabbinavar F, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006; 24: 34513457.
  • 4
    McCaffrey JA,Hilton S,Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15: 18531857.
  • 5
    Bamias A,Aravantinos G,Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004; 22: 220228.
  • 6
    Moore MJ,Tannock IF,Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997; 15: 34413445.
  • 7
    Stadler WM,Kuzel T,Roth B,Raghavan D,Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 33943398.
  • 8
    Shih C,Chen VJ,Gossett LS, et al. LY231514, a pyrrolo [2,3-d] pyrimidine-based anti-folate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997; 57: 11161123.
  • 9
    Niyikiza C,Baker SD,Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002; 1: 545552.
  • 10
    Paz-Ares L,Tabernero A,Moyano A, et al. A phase II study of the multi-targeted anti-folate MTA (LY231514) in patients with advanced transitional cell carcinoma of the bladder [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 339. Abstract 1307.
  • 11
    Adjei A,Erlichman C,Sloan J, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000; 18: 17481757.
  • 12
    Mey V,Giovannetti E,De Braud F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer. 2006; 95: 289297.
  • 13
    Smith T,Khatcheressian J,Lyman G, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. JClin Oncol. 2006; 24: 31873205.
  • 14
    Bajorin D,Dodd P,Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17: 31733181.
  • 15
    von der Maase H,Sengelov L,Roberts J, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 46024608.
  • 16
    Vaughn D,Manola J,Dreicer R, et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer. 2002; 95: 10221027.
  • 17
    Small E,Lew D,Redman B, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000; 18: 25372544.
  • 18
    Galsky M,Mironov S,Iasonos A,Scattergood J,Boyle M,Bajorin D. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007; 25: 265270.
  • 19
    von der Maase H,Lehmann J,Gravis G, et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol. 2006; 17: 15331538.